TLR9
Toll-like receptor 9
As of the edition of 20 October 2026, TLR9 (toll-like receptor 9, UniProt Q9NR96) has 13 drugs tested at it and 13 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NR96
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 3
- Disease areas
- Lungs and airways; Infections; Cancer; Skin and connective tissue; Immune system; Digestive system; Urinary and reproductive; Bones, joints and muscles
- Registered trials of its drugs
- 460
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 6 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Hydroxychloroquine | Marketed | Phase 4 | none listed |
| Agatolimod | Stopped | Phase 3 | none listed |
| Vidutolimod | Active | Phase 3 | none listed |
| Tilsotolimod | Stopped | Phase 3 | none listed |
| Lefitolimod | Stopped | Phase 3 | none listed |
| 1018 ISS | Marketed | Phase 2 | none listed |
| Cobitolimod | Stopped | Phase 3 | none listed |
| EMD-1201081 | Stopped | Phase 2 | none listed |
| Bazlitoran | Went quiet | Phase 2 | none listed |
| CPG10101 | Went quiet | Phase 2 | none listed |
| Cavrotolimod | Stopped | Phase 2 | none listed |
| AZD1419 | Went quiet | Phase 2 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 3 |
| Undetermined | 4 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| AbbVie | Route A |
| InDex Pharmaceuticals | Route A |
| Idera Pharmaceuticals | Route A |
The other 10 companies at TLR9
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at TLR9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.